Literature DB >> 119307

Parietal and chief cell sensitivity to histamine and pentagastrin stimulation before and after cimetidine treatment in healthy subjects.

E Aadland, A Berstad.   

Abstract

Gastric acid and pepsin output in response to 2.5 and 25.6 micrograms . kg-1h-1 of histamine dihydrochloride and 0.10 and 6.0 micrograms . kg-1h-1 of pentagastrin was studied before and after cessation of 4 weeks of cimetidine treatment, 1 g/day, in 10 healthy volunteers. Acid output in response to the low dose of histamine increased significantly from an average of 6.7 mmol +/- 1.3 mmol (S.E.M.) before to 10.1 mmol +/- 0.9 mmol after treatment (p = 0.02), whereas acid output in response to the maximal dose of histamine was not significantly different. Parietal cell sensitivity to histamine stimulation increased significantly after the treatment period from a mean of 28.2% +/- 3.2% before treatment to 49.3% +/- 2.8% afterwards (p less than 0.01). The results indicate augmented parietal cell sensitivity in response to histamine stimulation after withdrawal of cimetidine. Both acid output in response to the two doses of pentagastrin and parietal cell sensitivity to pentagastrin stimulation were not significantly different after cessation of cimetidine treatment. Pepsin output and chief cell sensitivity to histamine and pentagastrin stimulation were not significantly influenced by cimetidine treatment.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 119307

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Rebound intragastric hyperacidity after abrupt withdrawal of histamine H2 receptor blockade.

Authors:  C U Nwokolo; J T Smith; A M Sawyerr; R E Pounder
Journal:  Gut       Date:  1991-12       Impact factor: 23.059

2.  Increased parietal cell sensitivity after chronic treatment with ranitidine in the conscious cat.

Authors:  G Coruzzi; G Bertaccini
Journal:  Agents Actions       Date:  1989-11

3.  Rebound nocturnal hypersecretion after four weeks treatment with an H2 receptor antagonist.

Authors:  G M Fullarton; G McLauchlan; A Macdonald; G P Crean; K E McColl
Journal:  Gut       Date:  1989-04       Impact factor: 23.059

4.  Alteration of H2 receptor sensitivity in duodenal ulcer patients.

Authors:  I N Marks
Journal:  Gut       Date:  1989-05       Impact factor: 23.059

Review 5.  Optimizing acid suppression for treatment of acid-related diseases.

Authors:  R H Hunt; C Cederberg; J Dent; F Halter; C Howden; I N Marks; S Rune; R P Walt
Journal:  Dig Dis Sci       Date:  1995-02       Impact factor: 3.199

6.  Changes in nocturnal and peak acid outputs after duodenal ulcer healing with sucralfate or ranitidine.

Authors:  A F Kummer; D A Johnston; I N Marks; G O Young; N A Tigler-Wybrandi; S A Bridger
Journal:  Gut       Date:  1992-02       Impact factor: 23.059

7.  Gastric secretory conditions and plasma gastrin levels in rats after prolonged treatment with cimetidine.

Authors:  K Tabata; S Okabe
Journal:  Dig Dis Sci       Date:  1984-01       Impact factor: 3.199

8.  Tolerance and rebound to H2-receptor antagonists: intragastric acidity in patients with duodenal ulcer.

Authors:  C H Wilder-Smith; F Halter; H S Merki
Journal:  Dig Dis Sci       Date:  1991-12       Impact factor: 3.199

Review 9.  The H2-receptor antagonist era in duodenal ulcer disease.

Authors:  I N Marks
Journal:  Yale J Biol Med       Date:  1992 Nov-Dec
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.